External validation of the Dat'AIDS score: A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or older.
HIV infections/mortality
cohort studies
comorbidity
risk score
validation study
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
24 Aug 2023
24 Aug 2023
Historique:
received:
19
03
2023
accepted:
03
08
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
24
8
2023
Statut:
aheadofprint
Résumé
To perform an external validation of the Dat'AIDS score for predicting 5-year overall mortality among people with HIV (PWH) aged 60 years or older. This was a multi-centre prospective cohort study at all sites participating in the Swiss HIV Cohort Study (SHCS). We calculated the Dat'AIDS score in PWH aged 60 years or older at their first visit between 1 January 2015 and 1 January 2020. People living with HIV-2 and those whose Dat'AIDS score could not be calculated were excluded. Patients were followed until 1 January 2020. The primary endpoint was all-cause mortality. Vital status was collected throughout the study period. We obtained population and score descriptive statistics and assessed the score's discrimination and calibration. We included 2205 participants (82% male) of median [interquartile range (IQR)] age 62.0 (60.3-67.0) years, mostly with viraemia <50 copies/mL (92.7%). Median follow-up time was 15.9 years and median (IQR) CD4 cell count at enrolment was 586 (420-782) cells/μL. In all, 152 deaths were recorded during a total follow-up period of 7147 patient-years. The median (IQR) observed Dat'AIDS score was 3 (0-8). Discriminative capacities were good as the C-statistic was 0.73 (95% CI: 0.69-0.77) and consistent across all subgroups. Comparison of observed and expected survival probabilities showed good calibration. External validation of the Dat'AIDS score in patients aged 60 years or older showed that it could be a useful tool not only for research purposes, but also to identify older patients at a higher mortality risk and to tailor the most appropriate interventions.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Swiss National Science Foundation
ID : 201369
Pays : Switzerland
Informations de copyright
© 2023 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
May MT, Gompels M, Delpech V, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. Aids. 2014;28:1193-1202.
Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. Aids. 2014;28:1181-1191.
Smit M, Brinkman K, Geerlings S, et al. ATHENA observational cohort future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15:810-818.
Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120-1126.
Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59:1787-1797.
Hentzien M, Dramé M, Allavena C, et al. Impact of age-related comorbidities on five-year overall mortality among elderly HIV-infected patients in the late HAART era - role of chronic renal disease. J Nutr Health Aging. 2016;20:408-414.
Hentzien M, Dramé M, Delpierre C, et al. HIV-related excess mortality and age-related comorbidities in patients with HIV aged ≥60: a relative survival analysis in the French Dat'AIDS cohort. BMJ Open. 2019;9:e024841.
High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and aging working group. J Acquir Immune Defic Syndr. 2012;60(Suppl 1):S1-S18.
Hentzien M, Delpierre C, Pugliese P, et al. Derivation and internal validation of a mortality risk index for aged people living with HIV: the Dat'AIDS score. PloS One. 2018;13:e0195725.
Royston P, Altman DG. External validation of a cox prognostic model: principles and methods. BMC Med Res Methodol. 2013;13:33.
Scherrer AU, Traytel A, Braun DL, et al. Cohort profile update: the Swiss HIV cohort study (SHCS). Int J Epidemiol. 2022;51:33-34j.
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247:2543-2546.
Wong MCS, Ching JYL, Ng S, et al. The discriminatory capability of existing scores to predict advanced colorectal neoplasia: a prospective colonoscopy study of 5,899 screening participants. Sci Rep. 2016;6:20080.
Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. Ann Intern Med. 2003;139:959-965.
Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. Wiley; 2000.
Crowson CS, Atkinson EJ, Therneau TM. Assessing calibration of prognostic risk scores. Stat Methods Med Res. 2016;25:1692-1706.
McLernon DJ, Giardiello D, Van Calster B, et al. Assessing performance and clinical usefulness in prediction models with survival outcomes: practical guidance for cox proportional hazards models. Ann Intern Med. 2022;176:105-144. doi:10.7326/m2-2-0844
Therneau TM, Grambsch PM. The cox model. Modeling Survival Data: Extending the Cox Model. Springer New York; 2000:39-77.
Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. JOSS. 2019;4:1686.
Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162:55-63.
Hosmer DW, Lemeshow S, May S. Applied Survival Analysis: Regression Modeling of Time-to-Event Data. John Wiley & Sons, Inc.; 2008.
Justice AC, Modur SP, Tate JP, et al. Predictive accuracy of the veterans aging cohort study index for mortality with HIV infection: a north American cross cohort analysis. J Acquir Immune Defic Syndr. 2013;62:149-163.
McGinnis KA, Justice AC, Moore RD, et al. Discrimination and calibration of the Vacs index 2.0 for predicting mortality among people with HIV in North America. Clin Infect Dis. 2021;2021:ciab883.
Tate JP, Sterne JAC, Justice AC. Veterans aging cohort study (VACS) and the antiretroviral therapy cohort collaboration (ART-CC). Albumin, white blood cell count, and body mass index improve discrimination of mortality in HIV-positive individuals. Aids. 2019;33:903-912.
Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. Aids. 2013;27:563-572.
De Francesco D, Wit FW, Bürkle A, et al. Do people living with HIV experience greater age advancement than their HIV-negative counterparts? Aids. 2019;33:259-268.
Demontès M, Eymard Duvernay S, Allavena C, et al. Multimorbidity in elderly persons according to the year of diagnosis of human immunodeficiency virus infection: a cross-sectional Dat'AIDS cohort study. Clin Infect Dis. 2020;71:2880-2888.